Syneron Bio closed a $150 million Series B to fund its macrocyclic peptide development platform, building on earlier AstraZeneca-linked activity and a nearly $100 million prior raise. Separately, Ambrosia Biosciences secured an oversubscribed $100 million Series B to advance its lead oral small-molecule GLP-1 candidate into Phase I trials, with additional work planned across GIP and amylin targets. Together, the deals show capital continues to flow into modality diversification—peptides for targeted biology and oral small molecules for scalable cardiometabolic therapeutics. Both companies are signaling a “to clinic” timeline, which will matter for pipeline validation given the crowded obesity landscape. Investors will focus on differentiation plans (macrocycle engineering vs GPCR-combinability), early PK/PD readouts, and the strength of clinical endpoints once dose-finding begins.